Ethyl methylhydroxypyridine succinate inhibitor free radical processes - membranoprotector, which also possesses antihypoxic, stress-protective, nootropic, antiepileptic and anxiolytic action.
Antioxidant drug, regulating metabolic processes in the myocardium and vascular wall. The mechanism of action is due to antioxidant and membrane-protective properties. Suppresses peroxide oxidation of lipids, increases the activity of superoxidease, affects the physicochemical properties (phosphotidylserine and phosphotidylinosit, etc.) in the membrane, reduces the ratio of cholesterol / phospholipids, reduces the viscosity of the lipid layer and increases fluidity of the membrane, activates the energy-producing functions of mitochondria, and improves energy metabolism in the cell and thus protects the apparatus cells and the structure of their membranes. The change in the functional activity of the biological membrane caused by the drug leads to conformational changes in the protein macromolecules of synaptic membranes, as a result of which it has a modulating effect on the activity of membrane-bound enzymes, ion channels and receptor complexes,in particular, benzodiazepine, GABA, acetylcholine, enhancing their ability to bind to ligands, increasing the activity of neurotransmitters and activation of synaptic processes.
Enhances the compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in adenosine triphosphate (ATP) and creatine phosphate, activates the energy-producing function of mitochondria.
Increases the resistance of the body to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with ethanol and antipsychotic drugs). It improves the metabolism and blood supply of the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.
Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. Has hypolipidemic action, reduces the content of total cholesterol and low density lipoprotein (LDL).
Improves the functional state of the ischemic myocardium,reducing the manifestations of systolic and diastolic dysfunction of the left ventricle (LV), as well as electrical instability of the myocardium.
In conditions of a critical decline in coronary blood flow, structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes of phosphodiesterase, adenylate cyclase, acetylcholinesterase. It supports the activation of aerobic glycolysis in acute ischemia and promotes the reduction of mitochondrial oxidation-reduction processes in hypoxic conditions, increases the synthesis of adenosine triphosphate (ATP), creatine phosphate and other macroerges. Increases the collateral blood supply of the ischemic myocardium and activates the energosynthesizing processes in the ischemic zone, which contributes to maintaining the integrity of the cardiomyocytes and maintaining their functional activity.
Patients with stable angina increases exercise tolerance nitrates and anti-anginal activity, improves the rheological properties of the blood, reduces the incidence of acute coronary insufficiency.
Pyridoxine, entering the body, phosphorylated, converted to pyridoxal-5-phosphate and is part of the enzymes that carry out decarboxylation, transamination and racemization of amino acids, as well as enzymatic conversion sulfur-containing and hydroxylated amino acids. Participates in the metabolism; is necessary for the normal functioning of the central and peripheral nervous system. Pyridoxine participates in the exchange of tryptophan, methionine, cysteine, glutamic and other amino acids. It plays an important role in the exchange of histamine. Promotes the normalization of lipid metabolism.